eGene Inc. Completes Successful Study Of Rapid And Inexpensive Detection Of H5N1 Avian Flu Strain With Primers From Genome Institute of Singapore

IRVINE, Calif.--(BUSINESS WIRE)--eGene, Inc. (OTCBB:EGEI), a leading bioengineering company and developer of a compact and automated digital genetic analyzer, today announced that it had recently, using H5N1 avian influenza primers provided by the Genome Institute of Singapore, completed a successful application study that demonstrated that eGene’s HDA-GT12 Genetic Analyzer can successfully detect H5N1 avian influenza to as few as 10 viral RNA copies.